Technical Analysis for INVA - Innoviva, Inc.

Grade Last Price % Change Price Change
C 11.89 -0.08% -0.01
INVA closed down 0.08 percent on Monday, April 19, 2021, on 55 percent of normal volume. It was able to find support at its 50 day moving average. It was able to bounce off of its 200 day moving average, an important long-term support line.
Earnings due: Apr 27
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Flat Flat Flat
Historical INVA trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
200 DMA Support Bullish 0.00%
50 DMA Support Bullish 0.00%
Inside Day Range Contraction 0.00%
20 DMA Resistance Bearish -0.08%
200 DMA Support Bullish -0.08%
Crossed Above 50 DMA Bullish -0.08%
Up 3 Days in a Row Strength -0.08%
20 DMA Resistance Bearish 0.00%
50 DMA Resistance Bearish 0.00%
Older End-of-Day Signals for INVA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
50 DMA Support about 11 hours ago
200 DMA Support about 11 hours ago
10 DMA Support about 11 hours ago
Rose Above 10 DMA about 11 hours ago
20 DMA Resistance about 11 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Innoviva, Inc. Description

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Drugs Asthma Pulmonary Disease Novi Chronic Obstructive Pulmonary Disease Icos Glucocorticoids Treatment Of Chronic Obstructive Pulmonary Disease Corticosteroid Organofluorides Antero Respiratory Products Fluticasone

Is INVA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 15.62
52 Week Low 9.21
Average Volume 502,200
200-Day Moving Average 11.85
50-Day Moving Average 11.88
20-Day Moving Average 11.93
10-Day Moving Average 11.89
Average True Range 0.36
ADX 14.83
+DI 22.49
-DI 21.57
Chandelier Exit (Long, 3 ATRs ) 11.79
Chandelier Exit (Short, 3 ATRs ) 12.46
Upper Bollinger Band 12.39
Lower Bollinger Band 11.47
Percent B (%b) 0.46
BandWidth 7.74
MACD Line -0.02
MACD Signal Line 0.00
MACD Histogram -0.0173
Fundamentals Value
Market Cap 1.21 Billion
Num Shares 101 Million
EPS 1.91
Price-to-Earnings (P/E) Ratio 6.23
Price-to-Sales 3.72
Price-to-Book 2.21
PEG Ratio 0.24
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.37
Resistance 3 (R3) 12.34 12.14 12.29
Resistance 2 (R2) 12.14 12.02 12.16 12.26
Resistance 1 (R1) 12.02 11.95 11.92 12.05 12.24
Pivot Point 11.82 11.82 11.78 11.84 11.82
Support 1 (S1) 11.70 11.70 11.60 11.73 11.54
Support 2 (S2) 11.50 11.63 11.52 11.52
Support 3 (S3) 11.38 11.50 11.49
Support 4 (S4) 11.41